# CapsoVision, Inc (CV)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/capsovision-inc/ JSON: https://steadybase.io/company/capsovision-inc.json Checked Nov 10, 2026. Latest filing read: Aug 13, 2026.

## Company

- Legal name: CapsoVision, Inc
- Ticker: CV (Nasdaq)
- SEC CIK: 0001378325
- Industry: Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Headquarters: Saratoga, CA
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: capsovision.com
- Investor relations: https://investors.capsovision.com/
- LinkedIn: https://www.linkedin.com/company/capsovision-inc-
- Next earnings date: Nov 12, 2026

## Key facts

- Revenue: $13.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/0001378325-26-000010-index.html
- Operating income: -$25.5M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/0001378325-26-000010-index.html
- Net income: -$25.3M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/0001378325-26-000010-index.html
- SG&A: $14.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/0001378325-26-000010-index.html
- Employees: 99 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- Shares outstanding: 50,046,913 as of Aug 12, 2026 (10-Q filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000036/0001378325-26-000036-index.html
- Auditor: Baker Tilly Us, LLP, Santa Clara, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm

## Business

We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care. We are a Delaware company, incorporated in 2005. Our corporate headquarters is located in Saratoga, California.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $13.6M | -$25.5M | -$25.3M | $14.4M |
| Dec 31, 2024 | $11.8M | -$19.9M | -$19.9M | $11.2M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/capsovision-inc.json

## Officers and directors

- Kang-Huai (Johnny) Wang, Director, President and Chief Executive Officer (Principal Executive Officer). Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- David Garcia, Senior VP of Finance (Principal Financial Officer and Principal Accounting Officer). LinkedIn: https://www.linkedin.com/in/david-garcia-li. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- Chen Lung Tsai, Chairman of the Board of Directors. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- David Michael Garcia, Sr. VP of Finance. Source: Form 4 filed Jun 3, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000209311226000002/0002093112-26-000002-index.htm
- Douglas Patrick Atkinson, Head of Global Sales. Source: Form 4 filed Jun 3, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000207410526000004/0002074105-26-000004-index.htm
- Hui Ying (Patty) Kuo, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- Joanne Imperial, M.D., Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- Julia Gouw, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- Keri Jorgenson, Director of Clinical Operations. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- Michele Harari, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- Wen-Herng (Henry) King, Director. Source: 10-K filed Mar 26, 2026, https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm

## Recent 8-K events

- Sep 28, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000045/cv-20260925.htm
- Sep 18, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000043/cv-20260917.htm
- Aug 18, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000039/cv-20260813.htm
- Aug 13, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/cv-20260813.htm
- Jul 2, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000026/cv-20260701.htm
- Jun 12, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000023/cv-20260611.htm
- May 14, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000019/cv-20260514.htm
- Mar 26, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000008/cv-20260326.htm
- Mar 20, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.02, Results of operations and financial condition (earnings release); Item 3.02, Unregistered sales of equity securities; Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000004/cv-20260320.htm
- Mar 13, 2026: Item 1.01, Entry into a material definitive agreement; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000002/cv-20260313.htm

## What management said

- "The second quarter marked another important step in the evolution of CapsoVision as we advanced both our commercial execution and product innovation. We were pleased to launch AI Highlights™ internationally, providing physicians in Europe with an AI-assisted workflow solution that complements our CapsoCam Plus® platform and reinforces our long-term vision of integrated, AI-enabled capsule endoscopy" Johnny Wang, President and Chief Executive Officer of CapsoVision (8-K filed Aug 13, 2026). Source: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000035/cv-20260813xex991q22026ear.htm

## Latest filings

- 8-K filed Sep 28, 2026: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000045/cv-20260925.htm
- 10-K filed Mar 26, 2026: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000010/cv-20251231.htm
- 10-Q filed Aug 13, 2026: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000036/cv-20260630.htm
- DEF 14A filed Apr 28, 2026: https://www.sec.gov/Archives/edgar/data/1378325/000137832526000013/cv-20260427.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/